UNITED ~~STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549~~STATES

~~FORM~~SECURITIES ~~8-K~~AND EXCHANGE COMMISSION

~~CURRENT~~Washington, ~~REPORT~~D.C. 20549

~~Pursuant~~Form ~~to Section 13 or 15(d) of the Securities Exchange Act of 1934~~8-K

~~Date~~Current of Report ~~(Date of earliest event reported): October 30, 2025~~

~~PLUS~~Pursuant ~~THERAPEUTICS,~~to ~~INC.~~Section 13 or 15(d)

~~(Exact name~~ of ~~Registrant~~the asSecurities ~~Specified~~Exchange inAct ~~Its~~of ~~Charter)~~1934

Delaware	001-34375	33-0827593
(State or Other Jurisdictionof Incorporation)	(Commission File Number)	(IRS EmployerIdentification No.)
2710 REED ROADSuite 160
Houston, Texas		77051
(Address of Principal Executive Offices)		(Zip Code)

Date of Report (Date of earliest event reported): November 17, 2025

~~Registrant’s~~PLUS ~~Telephone Number~~THERAPEUTICS, ~~Including Area Code: (737) 255-7194~~INC.

(~~Former~~Exact ~~Name~~name orof ~~Former~~registrant ~~Address,~~as ifspecified ~~Changed~~in ~~Since~~its ~~Last Report~~charter)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Delaware

001-34375

33-0827593

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

☐2710 ~~Written~~Reed ~~communications~~Road, ~~pursuant~~Suite to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))160,

~~Securities~~Houston, ~~registered~~Texas ~~pursuant to Section 12(b) of the Act:~~77051

Title of each class		TradingSymbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		PSTV		The Nasdaq Capital Market

(Address of principal executive offices, with zip code)

~~Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933~~ (~~§ 230.405 of this chapter~~737) ~~or Rule 12b~~255-~~2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).~~ 7194

~~Emerging~~(Registrant’s ~~growth~~telephone ~~company~~number, ☐including area code)

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ N/A

~~Item~~(Former ~~2.02~~name ~~Results~~or offormer ~~Operations~~address, ~~and~~if ~~Financial~~changed ~~Condition.~~since last report)

OnCheck ~~October 30, 2025, Plus Therapeutics, Inc. (~~the ~~“Company”)~~appropriate ~~reported~~box ~~financial~~below ~~results~~if ~~for~~ the ~~third~~Form ~~quarter~~8-K ~~ended~~filing ~~September~~is ~~30,~~intended ~~2025~~to ~~and~~simultaneously ~~other~~satisfy ~~recent~~the ~~corporate~~filing ~~updates.~~obligation ~~A copy~~ of the ~~press~~registrant ~~release~~under isany ~~furnished~~of asthe ~~Exhibit~~following ~~99.1~~provisions to(see ~~this~~General ~~report~~Instructions ~~and incorporated by reference~~A.2. below):

~~The~~☐ ~~information~~Written incommunications ~~this~~pursuant ~~Item~~to ~~2.02~~Rule of425 ~~this~~under ~~Current Report on Form 8-K (including Exhibit 99.1) is furnished and shall not be deemed “filed” for purposes of Section 18 of~~ the Securities ~~Exchange~~ Act ~~of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12~~(~~a)(2)~~17 ofCFR ~~the Securities Act of 1933, as amended~~230. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, whether made before or after today’s date, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific references in such filing.425)

~~Item~~☐ ~~9.01~~Soliciting ~~Financial~~material ~~Statements~~pursuant ~~and~~to ~~Exhibits~~Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

(d) Exhibits.
ExhibitNumber		Description
99.1		Press Release Announcing Financial Results, dated October 30, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

~~SIGNATURES~~☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

~~Pursuant to the requirements of the~~ Securities ~~Exchange~~registered ~~Act~~pursuant ~~of 1934, the registrant has duly caused this report~~ to beSection 12(b) ~~signed~~of ~~on its behalf by~~ the ~~undersigned hereunto duly authorized.~~Act:

			PLUS THERAPEUTICS, INC.
Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Date:	October 30, 2025	By:	/s/ Marc H. Hedrick, M.D.
Common Stock, par value $0.001		PSTV		The Nasdaq Capital Market
			Marc H. Hedrick, M.D.President and Chief Executive Officer

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

Item 7.01.

Regulation FD Disclosure.

On November 17, 2025, Plus Therapeutics, Inc. (the “Company”) issued a press release announcing that it had received an additional 180-day extension period from the Nasdaq Listing Qualifications Department (the “Nasdaq Staff”) to regain compliance with the $1.00 minimum bid price bid requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”), discussed in more detail in Item 8.01 below.

The press release is furnished herewith as Exhibit 99.1 and incorporated by reference herein. The information contained in the press release is being furnished and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that Section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 8.01

Other Events.

As previously disclosed, on May 16, 2025, the Company received notice (the “Notification Letter”) from the Nasdaq Staff that, because the closing bid price for the Company’s common stock had fallen below $1.00 per share for 30 consecutive business days, the Company no longer complied with the Minimum Bid Price Requirement. The Notification Letter stated that the Company had 180 days, or until November 12, 2025, to demonstrate its compliance with the Minimum Bid Price Requirement.

On November 13, 2025, the Company received a second letter from the Nasdaq Staff advising that the Company had been granted an additional 180 calendar days, or until May 11, 2026, to regain compliance with the Minimum Bid Price Requirement, in accordance with Nasdaq Listing Rule 5810(c)(3)(A).

The Company intends to continue to actively monitor the closing bid price of its common stock and will evaluate available options to regain compliance with the Minimum Bid Price Requirement. Specifically, the Company has confirmed to The Nasdaq Stock Market LLC (“Nasdaq”) that, if necessary, it will implement a reverse stock split of its outstanding common stock to attempt to regain compliance. If the Company does not regain compliance within the additional compliance period, Nasdaq will provide notice that the Company’s common stock will be subject to delisting. The Company would then be entitled to appeal that determination to a Nasdaq hearings panel. There can be no assurance that the Company will regain compliance with the Minimum Bid Price Requirement during the 180-day additional compliance period or maintain compliance with the other Nasdaq listing requirements.

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits.


Exhibit No.		Description

99.1		Press release of the issuer dated November 17, 2025.

104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 17, 2025


PLUS THERAPEUTICS, INC.

By:		/s/ Marc H. Hedrick, M.D.
		Marc H. Hedrick, M.D. President and Chief Executive Officer

Filing Compare · PLUS THERAPEUTICS, INC.